These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 17873349)

  • 1. Mammary stem cells and breast cancer--role of Notch signalling.
    Farnie G; Clarke RB
    Stem Cell Rev; 2007 Jun; 3(2):169-75. PubMed ID: 17873349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer.
    McGowan PM; Simedrea C; Ribot EJ; Foster PJ; Palmieri D; Steeg PS; Allan AL; Chambers AF
    Mol Cancer Res; 2011 Jul; 9(7):834-44. PubMed ID: 21665937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.
    Farnie G; Clarke RB; Spence K; Pinnock N; Brennan K; Anderson NG; Bundred NJ
    J Natl Cancer Inst; 2007 Apr; 99(8):616-27. PubMed ID: 17440163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
    Farnie G; Willan PM; Clarke RB; Bundred NJ
    PLoS One; 2013; 8(2):e56840. PubMed ID: 23457626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
    Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
    Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of ΔNp63α induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway.
    Du Z; Li J; Wang L; Bian C; Wang Q; Liao L; Dou X; Bian X; Zhao RC
    Cancer Sci; 2010 Nov; 101(11):2417-24. PubMed ID: 20950370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
    Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
    EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland.
    Sansone P; Storci G; Tavolari S; Guarnieri T; Giovannini C; Taffurelli M; Ceccarelli C; Santini D; Paterini P; Marcu KB; Chieco P; Bonafè M
    J Clin Invest; 2007 Dec; 117(12):3988-4002. PubMed ID: 18060036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
    Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
    J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
    Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
    J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ.
    Ory V; Tassi E; Cavalli LR; Sharif GM; Saenz F; Baker T; Schmidt MO; Mueller SC; Furth PA; Wellstein A; Riegel AT
    Oncogene; 2014 Jun; 33(23):3033-42. PubMed ID: 23851504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.
    Phillips TM; McBride WH; Pajonk F
    J Natl Cancer Inst; 2006 Dec; 98(24):1777-85. PubMed ID: 17179479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Notch1 mRNA and protein expression in human breast cancer and normal mammary gland tissues].
    Hua BL; Fu XG; Hu WH; Yin L; Kang XL; Li HA; Jiang JF; Li F
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):806-9. PubMed ID: 20193454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
    Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.
    Li Q; Eades G; Yao Y; Zhang Y; Zhou Q
    J Biol Chem; 2014 Jan; 289(3):1303-12. PubMed ID: 24297178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.
    Smit L; Berns K; Spence K; Ryder WD; Zeps N; Madiredjo M; Beijersbergen R; Bernards R; Clarke RB
    Oncotarget; 2016 Jan; 7(3):2596-610. PubMed ID: 26595803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors.
    Ling H; Sylvestre JR; Jolicoeur P
    Oncogene; 2010 Aug; 29(32):4543-54. PubMed ID: 20562911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.
    Won HY; Lee JY; Shin DH; Park JH; Nam JS; Kim HC; Kong G
    FASEB J; 2012 Dec; 26(12):5002-13. PubMed ID: 22954590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.